Summary
Cencora, Inc. (formerly AmerisourceBergen Corporation) reported strong performance for the fiscal year ended September 30, 2003. The company experienced a significant 13% increase in operating revenue, reaching $45.5 billion, driven primarily by its Pharmaceutical Distribution segment. This growth was supported by favorable industry trends such as an aging population and the introduction of new pharmaceuticals. The company also continued its strategic growth through several key acquisitions, including Bridge Medical, US Bioservices Corporation, and Anderson Packaging Inc., enhancing its service offerings and market position. Despite a slight decrease in gross profit margin to 4.93% due to competitive pricing and changes in customer mix, AmerisourceBergen successfully improved operating income by 23% to $883.1 million. This was achieved through operational efficiencies, cost reductions stemming from merger integration, and a focus on lowering its operating expense ratio. The company also maintained its quarterly cash dividend, signaling confidence in its financial stability and future prospects.
Key Highlights
- 1Operating revenue increased by 13% to $45.5 billion for the fiscal year ended September 30, 2003.
- 2Operating income grew by 23% to $883.1 million, demonstrating improved profitability.
- 3The company completed several strategic acquisitions during the year, including Bridge Medical, US Bioservices Corporation, and Anderson Packaging Inc., to expand its service capabilities.
- 4Gross profit margin slightly decreased to 4.93% from 5.03% in the prior year, attributed to customer mix changes and competitive pressures.
- 5Distribution, selling, and administrative expenses as a percentage of revenue decreased to 2.98% from 3.19%, reflecting operational efficiencies.
- 6The company continued to pay quarterly cash dividends of $0.025 per share.
- 7AmerisourceBergen is actively consolidating its distribution network, aiming to reduce the number of facilities from 51 to 30 over the next three to four years through the 'Optimiz' program.